SCHEMBL5122264

SCHEMBL5122264

Cc1csc2nc(-n3cncn3)nc(NCc3ccc(F)cc3)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.48
PDE10A Q9Y233 2/20 0.39
CHRM4 P08173 1/20 0.38
RXFP1 Q9HBX9 1/20 0.36
KDM4E B2RXH2 2/20 0.36
TP53 P04637 2/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HRH4 Q9H3N8 1/20 0.35
CTNNB1 P35222 2/20 0.34
TCF7L2 Q9NQB0 2/20 0.34
LMNA P02545 2/20 0.34
ABL1 P00519 1/20 0.34
FYN P06241 1/20 0.34
SRC P12931 1/20 0.34
FLT3 P36888 1/20 0.34
POLB P06746 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5129121 0.90 ESR1 (0.47) ESR1PDE10ACHRM4RXFP1TSHR
SCHEMBL5122240 0.85 ESR1 (0.48) ESR1PDE10A
SCHEMBL5123189 0.84 ESR1 (0.49) ESR1CHRM4RXFP1TP53MAPK1
SCHEMBL5118514 0.84 GAA (0.46) PDE10ACHRM4RXFP1KDM4ETP53
SCHEMBL5124390 0.84 TNF (0.44) ESR1POLBMEN1KMT2AAPP
SCHEMBL5122170 0.82 ESR1 (0.49) ESR1CHRM4
SCHEMBL5127699 0.82 CHRM4 (0.42) ESR1PDE10ACHRM4KDM4ETP53
SCHEMBL5121170 0.82 TSHR (0.44) ESR1KDM4ETP53TSHRMAPK1
SCHEMBL5130532 0.82 CHRM4 (0.39) ESR1PDE10ACHRM4RXFP1KDM4E
SCHEMBL5122841 0.81 ESR1 (0.45) ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ESR1 2256/4885PDE10A 3363/4885CHRM4 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.